论文部分内容阅读
目的探讨布地奈德雾化吸入治疗急性喉炎的疗效及安全性。方法选择2006年1月~2010年12月就诊的急性喉炎患儿80例,随机分为布地奈德组和对照组。两组患儿均予以抗病毒药物和抗生素治疗。布地奈德组在此治疗的基础上加用布地奈德混悬液1~2mL(0.5~1mg)雾化吸入,每天2次。对照组在此治疗的基础上加用地塞米松静脉注射0.25~1.0mg/次,每天2次,疗效均为3d。观察两组患儿治疗后吸气性喉喘鸣、声嘶、犬吠样咳嗽等症状的缓解时间,并进行临床疗效的评定。结果布地奈德组患儿吸气性喉喘鸣、声嘶、犬吠样咳嗽等症状的缓解时间明显短于对照组(P<0.05)。布地奈德组的临床总有效率明显高于对照组(χ2=9.40,P<0.01)。两组患者在治疗期间未发生明显的不良反应。结论布地奈德混悬液雾化吸入治疗急性喉炎的疗效显著,能明显改善患者临床症状,安全性较好。
Objective To investigate the efficacy and safety of inhaled budesonide in the treatment of acute laryngitis. Methods Eighty children with acute laryngitis treated from January 2006 to December 2010 were randomly divided into budesonide group and control group. Both groups were treated with antivirals and antibiotics. Budesonide group on the basis of this treatment plus budesonide suspension 1 ~ 2mL (0.5 ~ 1mg) inhalation, 2 times a day. The control group on the basis of this treatment plus dexamethasone intravenous injection of 0.25 ~ 1.0mg / time, 2 times a day, the effect was 3d. After treatment, the relief rate of inspiratory laryngeal wheeze, hoarseness, bark-like cough and other symptoms were observed and the clinical efficacy was evaluated. Results The relief time of inhalation laryngeal wheeze, hoarseness, bark-like cough in the budesonide group was significantly shorter than that in the control group (P <0.05). The total effective rate of budesonide group was significantly higher than that of control group (χ2 = 9.40, P <0.01). Two groups of patients during the treatment did not occur significant adverse reactions. Conclusion The efficacy of budesonide suspension inhalation in the treatment of acute laryngitis is significant, which can significantly improve the clinical symptoms and safety of patients.